Lung Transplant Week

HomePatientsLung Disease Week at the ATS2017 ▶ Lung Transplant Week
Lung Transplant Week

Lung Transplant Week

Welcome Message

The American Thoracic Society and the Lung Transplant Foundation would like to welcome you to Lung Transplant week at the ATS.

We are pleased to update you on this life-saving treatment option for patients with chronic lung disease.

Lung transplantation remains a viable treatment option for patients with progressive and chronic lung disease.  The International Society for Heart and Lung Transplantation (2017) reports that through June 30, 2016, a total of 62,456 patients have received lung transplants. In 2015, there were over 4000 lung transplants performed in 152 lung transplant centers worldwide. Approximately 31% of adult recipients receive a lung transplant for chronic obstructive pulmonary disease (COPD), 24.8% for idiopathic interstitial pneumonia and 15.6% for cystic fibrosis. The median age of lung transplant recipients has steadily climbed over the past 30 years from 43 years old to 58 years old in 2015.

The median survival rate for adult transplant recipients is 5.9 years and 5.4 years for children.  Median survival has been steadily improving over the years and has risen from 4.3 years between 1990 and 1998 to 6.2 years between 1999 and 2008. The development of better immunosuppressive therapies and ways to manage rejection and infection have helped to improve the survival and quality of life of lung transplant recipients.  Support from the ATS and Lung Transplant Foundation will continue to improve both survival and quality of life amongst lung transplant recipients of all ages.

We hope that Lung Transplant Week at the American Thoracic Society will help increase the public awareness of lung transplantation, which will continue to advance ongoing research and treatments.


Eileen G. Collins, PhD, RN

Eileen G. Collins, PhD, RN
Professor, Department of Biobehavioral Health Science
College of Nursing
University of Illinois at Chicago
Member, ATS Board of Directors

Jeff Goldstein

Jeff Goldstein
President/Founder, Lung Transplant Foundation
Member, ATS Public Advisory Roundtable




The Lung Transplant Foundation (LTF) was founded as a non-profit organization by a group of lung transplant recipients from Durham and Chapel Hill, NC. These recipients from Duke University and UNC Hospitals realized promotion and funding of research to improve the post lung transplant experience and long term outcomes was severely lacking, so they created the LTF to tackle one of the most difficult and life-threatening issues facing transplant recipients, chronic rejection or bronchiolitis obliterans syndrome (BOS).